MIRA CFO Andriy Mushak files initial Form 3

MIRA PHARMACEUTICALS, INC. filed an initial ownership report (Form 3) for Andriy Mushak, who serves as Chief Financial Officer.

Accepted by SEC EDGAR 06/09/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

MIRA PHARMACEUTICALS, INC. filed an initial ownership report (Form 3) for Andriy Mushak, who serves as Chief Financial Officer. The filing does not list any transactions or holdings, functioning primarily as a baseline disclosure of his status as an officer subject to insider reporting rules.

Key Terms

Form 3, Chief Financial Officer, insider reporting

3 terms

Form 3 regulatory

"filed an initial ownership report (Form 3) for Andriy Mushak"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Financial Officer financial

"Andriy Mushak, who serves as Chief Financial Officer"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

insider reporting regulatory

"his status as an officer subject to insider reporting rules"

Insider reporting is the public disclosure of stock trades and holdings by a company’s executives, directors or large shareholders, filed with market regulators so investors can see when people with inside knowledge buy or sell. It matters because these actions can signal confidence or concern about a company’s future—much like a shop owner restocking or clearing shelves, insiders’ moves give clues about how those closest to the business view its prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the MIRA Form 3 filing for Andriy Mushak show?

The Form 3 filing lists Andriy Mushak as Chief Financial Officer of MIRA PHARMACEUTICALS, INC. It establishes him as an insider subject to reporting rules but does not detail any current stock or option transactions in this specific disclosure.

Does the MIRA Form 3 for Andriy Mushak report any share purchases or sales?

No, the Form 3 for Andriy Mushak shows zero buy, sell, acquire, dispose, or other transaction counts. It serves as an initial ownership report without recorded trading activity or derivative exercises in the data provided for this filing.

What insider role does Andriy Mushak hold at MIRA PHARMACEUTICALS (MIRA)?

The filing identifies Andriy Mushak as an officer of MIRA PHARMACEUTICALS, specifically holding the title of Chief Financial Officer. This role subjects him to ongoing SEC reporting obligations regarding his beneficial ownership and future transactions in the company’s securities.

Are any derivative securities reported for Andriy Mushak in this MIRA Form 3?

No derivative securities are listed for Andriy Mushak in the provided Form 3 data. The derivative summary is empty, and the exercise and derivative transaction counts are zero, indicating no reported options, warrants, or similar instruments in this particular filing.

What does the transaction summary indicate in the MIRA Form 3 for Andriy Mushak?

The transaction summary shows zero for all buy, sell, exercise, gift, tax withholding, and restructuring categories, with a neutral net buy-sell direction. This indicates there were no reportable transactions associated with this initial ownership filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mushak Andriy

(Last) (First) (Middle)

1200 BRICKELL AVENUE,

SUITE 1950 #1183

(Street)

MIAMI FLORIDA 33131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/02/2026

3. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC. [ MIRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Andriy Mushak	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)